Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib Or Nilotinib as First-Line Therapy in the United States

Authors

Karen Seiter, New York Medical CollegeFollow
D Latremouille-Viau
A Guerin
B Ndife
K Habucky
G J. Joseph
I Pivneva
P Gagnon-Sanschagrin
D H. Tang

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

5-2018

DOI

10.1016/j.jval.2018.04.176

Journal Title

Value in Health

Department

Medicine

Recommended Citation

Seiter, K., Latremouille-Viau, D., Guerin, A., Ndife, B., Habucky, K., Joseph, G. J., Pivneva, I., Gagnon-Sanschagrin, P., & Tang, D. H. (2018). Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib Or Nilotinib as First-Line Therapy in the United States. Value in Health, 21 (Suppl. 1), S28. https://doi.org/10.1016/j.jval.2018.04.176